

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 April 2011 (14.04.2011)

(10) International Publication Number
WO 2011/042560 A1

PCT

(51) International Patent Classification:

C07D 471/08 (2006.01) **A61K 31/439** (2006.01)
A61K 31/4188 (2006.01) **A61K 31/551** (2006.01)

(21) International Application Number:

PCT/EP2010/065147

(22) International Filing Date:

8 October 2010 (08.10.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0904864 9 October 2009 (09.10.2009) FR
61/263,663 23 November 2009 (23.11.2009) US

(71) Applicants (for all designated States except US):
NOVEXEL SA [FR/FR]; 102 Avenue Gaston Roussel,
F-93230 Romainville (FR). **FOREST LABORATO-**
RIES HOLDINGS LIMITED [IE/—]; 18 Parliament
Street, Milner House, Hamilton, Bermuda HM12 (BM).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BHAT-**
TACHARYA, Sisir [IN/US]; 558A New Highway, Apt.
1H, Hauppauge, New York 11788 (US). **BONNET,**
Alain [FR/FR]; 13 Impasse Forte-Maison, Nogentel,
F-02400 Chateau-Thierry (FR). **DEDHIYA, Mahendra,**
G. [US/US]; 1 Lea Court, Pomona, New York 10970
(US). **DUCANDAS, Véronique** [FR/FR]; 141 Avenue
Rouget de l'Isle, F-94400 Vitry Sur Seine (FR). **GIU-**
LIANI, Alexandre [FR/FR]; 13 Allée des Tilleuls,
F-94440 Villecresnes (FR). **PRIOUR, Alain** [FR/FR];
61, Bis Quai de la Seine, F-75019 Paris (FR). **RAVAUX,**
Valérie [FR/FR]; 816 Chemin de Veissieux Le Haut,

F-01600 Reyrieux (FR). **SPARGO, Peter** [GB/GB]; 22
Walmer Way, Deal Kent CT14 9QT (GB).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROP-**
ERTY; AstraZeneca AB, SE-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,
ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: POLYMORPHIC AND PSEUDOPOLYMORPHIC FORMS OF A PHARMACEUTICAL COMPOUND

(57) Abstract: The invention relates to the sodium salt of (1R,2S,5R)-7-oxo-6-sulfooxy-1,6- diazabicyclo[3.2.1]octane-2-carbox-
amide in hydrated or anhydrous crystallized enantiomeric form and in particular in the novel crystallized polymorphic and pseu-
dopolymorphic forms "A", "B", "D" and "E" defined in the application, as well as the method of preparation. The compound of
the invention can be used as a medicament, in particular a beta-lactamase inhibitor.



WO 2011/042560 A1